hero section gradient
15 handpicked stocks

Pharma's American Reshoring Wave

AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.

Author avatar

Han Tan | Market Analyst

Published on July 23

Your Basket's Financial Footprint

Market capitalisation breakdown for the basket 'Pharma's American Reshoring Wave'.

Key Takeaways for Investors:
  • Large-cap dominance likely reduces volatility, offering broader market‑like exposure and generally lower short-term risk.
  • Treat as a core holding for portfolio stability; it tends to suit long-term allocations, not speculative trades.
  • Expect steady, long-term value growth rather than explosive short-term gains; returns are likely moderate.
Total Market Cap
  • TMO: $210.70B

  • RGEN: $8.82B

  • AVTR: $10.64B

  • Other

About This Group of Stocks

1

Our Expert Thinking

AstraZeneca's massive $50 billion U.S. investment signals a major shift toward domestic pharmaceutical manufacturing. This trend, driven by tariff policies and supply chain resilience needs, creates a ripple effect across the entire biopharmaceutical ecosystem. We see this as a transformative moment that will benefit companies throughout the value chain.

2

What You Need to Know

This group focuses on the enablers of pharmaceutical reshoring rather than just the drug makers themselves. These companies build facilities, manufacture specialized equipment, and supply critical materials needed for domestic biopharmaceutical production. It's a play on the infrastructure and tools required for this industrial shift.

3

Why These Stocks

Each company was selected for its direct role in supporting pharmaceutical manufacturing expansion. From life sciences equipment makers to facility builders and raw material suppliers, these stocks are positioned to capture demand from large-scale capital projects as the industry builds out domestic capacity.

Why You'll Want to Watch These Stocks

🏭

Manufacturing Renaissance

AstraZeneca's $50 billion commitment is just the beginning. This massive investment could trigger a wave of similar moves by other pharmaceutical giants, creating sustained demand for the companies that build and equip these facilities.

Policy-Driven Momentum

U.S. tariff policies and supply chain security concerns are driving this reshoring trend. These aren't temporary market shifts but strategic moves backed by government support and long-term industrial policy.

🎯

Infrastructure Play

While everyone focuses on the drug makers, the real opportunity might be in the picks and shovels. These companies provide the essential tools, equipment, and services that make pharmaceutical manufacturing possible.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions